Tulsi Gabbard Says U.S. Funded 120+ Overseas Biolabs

Director of National Intelligence Tulsi Gabbard says the U.S. government funded more than 120 biolabs across over 30 countries. That June 12, 2026 release turned a long-running argument into a fresh national security story.

For many Americans, the issue goes far beyond lab maps. It touches public money, risky pathogen work, hidden decisions, and whether officials gave the public a straight answer. For readers of Patriot Press and others who already distrust official spin, that hits a nerve. The details behind the claim matter, so the scope of this disclosure is the right place to start.

What Gabbard says the overseas biolabs reveal about U.S. funding

Gabbard says ODNI staff spent months reviewing intelligence holdings and old files, then released declassified material that points to a broad U.S.-backed lab network overseas. According to the release, this was not a small aid program or one-off partnership. It was long-term support tied to dozens of countries, with Ukraine named as one of the most sensitive cases.

This quick snapshot shows why the release landed so hard:

The main takeaway is simple. Gabbard is presenting this as evidence of a large taxpayer-funded network, not an isolated case.

More than 120 labs across 30-plus countries

A number that high changes the frame of the debate. People can argue over one facility, one contract, or one foreign partner. A network spread across 30-plus countries is harder to wave away.

That scale raises basic questions. Which agencies paid for what work? Which contractors or partners managed the sites? What kind of reporting went back to Washington? Just as important, what did lawmakers and the public know at the time?

A network this wide also makes oversight harder. When money, samples, and research cross borders, responsibility can get blurry. That is one reason this disclosure carries so much force.

Why Ukraine is one of the most sensitive examples

Ukraine stands out because war changes the risk. The ODNI release says earlier intelligence warnings flagged at least one U.S.-funded lab there as vulnerable to Russian attack, seizure, or damage while holding dangerous pathogens.

That does not mean a disaster happened. It does mean officials knew a conflict zone carried extra danger. A lab that handles risky biological material needs steady security, stable power, trained staff, and clear chains of control. War disrupts every one of those conditions.

Because of that, Ukraine became more than a policy footnote. It became the example many readers remember first.

The biggest questions around gain-of-function research and oversight

The sharpest concern is not the word "biolab" by itself. The concern is what kind of work happened inside some of those facilities, who approved it, and how closely it was watched.

What gain-of-function research means in simple terms

Gain-of-function research is a simple idea with high stakes. It refers to experiments that can make a germ easier to spread, more harmful, or better able to survive, so scientists can study how it behaves.

Supporters say this can help prepare for outbreaks. Critics say the risk is obvious. If you make a dangerous pathogen more dangerous, even for research, a mistake or security failure could have huge costs.

The ODNI release says some U.S.-funded overseas labs worked with hazardous and highly contagious pathogens. It also says some of that work may have included gain-of-function research with limited visibility. That is why the argument is so intense.

Why oversight and public visibility are central concerns

When taxpayers fund risky work, oversight cannot be loose. People want to know where the money went, what rules applied, and who signed off on the research. Lawmakers want that too, because public health projects can turn into security issues fast.

Gabbard's office says new intelligence collection is already surfacing details about clinical trials tied to some facilities. That adds ethical and financial questions on top of the safety questions. Meanwhile, President Trump signed Executive Order 14292 on May 25, 2025, which aimed to halt federal funding for gain-of-function research around the world.

The fight is over more than lab addresses. It is about what the government funded, what it knew, and what it told the public.

How this disclosure could affect Fauci, Biden-era officials, and public trust

The politics were unavoidable the moment the release named a hidden history and accused past leaders of withholding facts. Still, the larger issue is trust. Once people believe officials minimized a real program, every earlier statement gets re-read through a harsher lens.

Why critics are pointing to past denials

Critics are comparing this release with old public messaging from health officials and Biden-era national security figures. Many people remember earlier debates where concerns about overseas labs were brushed aside or treated like fringe claims.

That is why names like Anthony Fauci are back in the argument. For some Americans, the ODNI release confirms a long-held belief that key facts were hidden in plain sight. Others will want a full paper trail before they accept every charge in the release. Both reactions are easy to understand.

For Patriot Press readers, the frustration is familiar. It is less about one official and more about a pattern of dismissal followed by partial disclosure.

What calls for accountability may look like next

The next phase will likely be procedural, not dramatic. Congress may push for hearings, sworn testimony, and a clearer funding map. Committees could ask which agencies approved the work, which foreign partners hosted it, and what safeguards were in place.

Further declassification is also likely. A first release often opens the door to more document requests, inspector reviews, and battles over redactions. If the claims hold up, pressure will grow for a full record of who made the decisions and why.

That matters because public trust does not come back with one press release. It comes back when the record is complete.

What American readers should watch for next

If you are trying to follow this story without getting buried in noise, focus on documents, timelines, and named decision-makers. Those details will separate a broad accusation from a fully established record.

The documents and details that still need confirmation

A large disclosure can answer one question and open five more. Readers should watch for specific lab locations, the kinds of pathogens handled, the dates of key grants or contracts, and the agencies that approved the work.

A few details will matter more than the rest:

• Clear timelines that show when funding began and who renewed it.

• Written safety rules for labs handling dangerous pathogens.

• Records that show what U.S. officials knew about war-zone risks in Ukraine.

• Evidence on whether gain-of-function work took place and under what review process.

The story will get sharper as those points come into focus.

Why the public wants a full and honest explanation

Most Americans are not asking for perfect policy. They are asking for honesty. If Washington funded a large overseas lab network that handled risky biological work, people expect clear disclosure and strict control.

That is why this story keeps growing. The strongest public concern is not only about what happened inside the labs. It is about whether the government was open about the program at all. For many Patriot Press readers, that is the center of the problem, and it is the reason this issue will not fade soon.

Conclusion

Gabbard's disclosure matters because of its scale. A claim of more than 120 U.S.-funded overseas biolabs shifts the argument from rumor to record, even if many details still need proof.

The hardest questions now center on oversight, gain-of-function research, and public trust. Americans want to know what was funded, where it happened, and whether officials were candid about the risks. Until those answers are complete, this story will remain a live test of government transparency.